BOSENTOR 125mg Price

Overview

Welcome to Dwaey, specifically on BOSENTOR 125mg Tablets/Film-coated page.
This medicine contains an important and useful components, as it consists of Bosentan (as monohydrate).
BOSENTOR 125mg is available in the market in concentration 125mg/Tablet and in the form of Tablets/Film-coated.

PHARMASCIENCE INC is the producer of BOSENTOR 125mg and it is imported from CANADA, The most popular alternatives of BOSENTOR 125mg are listed downward .

Mode Of Action

Competitive antagonist of endothelin-1; blocks endothelin receptors on vascular endothelium and smooth muscle resulting in inhibition of vasoconstriction

Indication

• Pulmonary Arterial Hypertension (PAH)

Precaution

Hepatotoxicity and teratogenicity. Elevations of AST or ALT associated with Bosentan are dose-dependent, occur both early and late in treatment, usually progress slowly, are typically asymptomatic, and usually have been reversible after treatment interruption or cessation. Aminotransferase elevations also may reverse spontaneously while continuing treatment with Tracleer. Liver aminotransferase levels must be measured prior to initiation of treatment and then monthly and therapy adjusted accordingly .Discontinue Bosentan if liver aminotransferase elevations are accompanied by clinical symptoms of hepatotoxicity (such as nausea, vomiting, fever, abdominal pain, jaundice, or unusual lethargy or fatigue) or increases in bilirubin > 2 Lactation: Not known if excreted in breast milk; not recommended

Side Effects

• >10% Hgb decreased; >1 g/dL (57%)
• Inhibition of spermatogenesis (25%)
• Headache (16-22%)
• Nasopharyngitis (11%)
• Transaminses increased (12%)
• Respiratory tract infection (22%)
• Increased transaminases (12%) 1-10% Edema
• lower limb (5-8%)
• Flushing (7-9%)
• Hypotension (7%)
• Hepatic abnormalities (4%)
• Palpitations (4%)
• Anemia (3%)
• Dyspepsia (4%)
• Edema
• general (4%)
• Fatigue (2%)
• Pruritus (4%) <1% Hyperbilirubinemia
• Vasculitis
• Jaundice
• Leukopenia
• Thrombocytopenia
• Leukocytoplastic

Contra indication

Patients with WHO Class II symptoms showed reduction in the rate of clinical deterioration and a trend for improvement in walk distance. Physicians should consider whether these benefits are sufficient to offset the risk of hepatotoxicity in WHO Class II patients, which may preclude future use as their disease progresses.

Pregnancy and lactation

Pregnancy category: X

Studies in animals or humans have demonstrated fetal abnormalities and/or there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience, and the risks involved in use of the drug in pregnant women clearly outweigh potential benefits.